- Today, let’s take a look atshengnuo biotechnology on the Sci-tech Innovation Board.
- The company has a full-process R&D pipeline and a full-industry chain platform for peptide APIs and preparations, and can provide pharmaceutical research services for innovative peptide drugs and generic drugs from process route design to small-scale, pilot-scale, process verification and quality research, and The entire chain of customized production services for APIs and preparation products required for drug R&D and commercial production covers the complete drug development cycle from drug discovery, preclinical research, to clinical trials and marketing.
Today, let’s take a look atshengnuo biotechnology on the Sci-tech Innovation Board.
The company is a high-tech enterprise with core peptide synthesis and modification technologies. It has advanced and efficient peptide drug technology research and development and large-scale production capabilities. The company’s main business is independent research and development, production and sales of peptide APIs and preparation products with large market capacity and strong competitiveness at home and abroad.
At the same time, the company relies on its technological advantages in the field of peptide drug research and development and large-scale production. Foreign pharmaceutical companies provide pharmaceutical research services for innovative peptide drugs, customized production services for peptide products, and technology transfer services for peptide drug production. In addition, the company also provides small-molecule chemical drug levosimendan preparations on behalf of processing and levosimendan bulk drug production, export sales business.
The company has a full-process R&D pipeline and a full-industry chain platform for peptide APIs and preparations, and can provide pharmaceutical research services for innovative peptide drugs and generic drugs from process route design to small-scale, pilot-scale, process verification and quality research, and The entire chain of customized production services for APIs and preparation products required for drug R&D and commercial production covers the complete drug development cycle from drug discovery, preclinical research, to clinical trials and marketing.
Relying on the core technology advantages of peptide synthesis and modification, the company has gained a high reputation and recognition in the field of peptide drug development and production. It has successively provided 30 new drug R&D companies and scientific research institutions such as Suzhou Paige Biotech, Biotech Biotech, and Bajiayi. Pharmaceutical research and customized production services for more than projects, of which one innovative peptide drug has been approved and entered the commercialization stage, and another seven innovative peptide drugs have entered the clinical trial stage.
The company selects peptide generic drugs with large market capacity and strong market competitiveness at home and abroad for research and development, and has mastered the large-scale production technology of 15 varieties of APIs, of which 7 varieties have obtained domestic production approvals and 8 varieties Obtained the US DMF registration (activated status), and the extended development of 8 peptide preparations has obtained 12 domestic production approvals.
The products cover immunity, digestive tract, antiviral, obstetrics and gynecology, diabetes, cardiovascular and cerebrovascular, rare diseases, orthopedics And so on in areas where peptide drugs play an important role. Enfuvirtide and carbetocin injections for injection of the company’s peptide preparation products are the first imitation peptide drugs in China;
synthesis of bivalrudine, liraglutide, thymosin, icatibant, enfuvirtide, etc. The more difficult generic APIs have been exported to international markets such as Europe, America, India, South Korea and other international markets. The end customers include Fresenius, Aurobindo, Mylan, Lupin, and Sinopec. Litai, Shanghai First Biochemical, Yangtze River and other well-known pharmaceutical companies at home and abroad; the industrialized research and development of five varieties of atosiban acetate, octreotide acetate, somatostatin, thymofaxine and carbetocin were included in “‘ The Eleventh Five-Year “National Major New Drug Development Project”;
the two preparations of icatibant and posaconazole that the company has submitted drug registration applications are listed in the “First Batch of Encouraged Generic Drugs List” by the National Health Commission.